^
    Back
    Association details:
    Biomarker:ALK wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Ono Pharmaceuticals Press Release
    Title:

    Opdivo® Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Combination with Chemotherapy in Taiwan

    Published date:
    02/22/2023
    Excerpt:
    Ono Pharmaceutical...announced that Ono Pharma Taiwan Co., Ltd., a Taiwanese subsidiary of ONO, received the approval of Opdivo® (nivolumab) Intravenous Infusion ("Opdivo"), a human anti-human PD-1 monoclonal antibody, on February 21, 2023 in Taiwan from the Taiwan Food and Drug Administration (TFDA), for neoadjuvant treatment of adult patients with resectable (tumors ≥4cm or node positive) and without EGFR or ALK genomic tumor aberrations non-small cell lung cancer in combination with platinum-doublet chemotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Induction Chemo-Nivo in Unresectable Stage III NSCLC

    Excerpt:
    ...- EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes...
    Trial ID:
    NCT06003075